Kedalion Therapeutics to Present at 2018 BIO Investor Forum
MENLO PARK, Calif.--(BUSINESS WIRE)--Oct 10, 2018--Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced that Peter Noymer, PhD, the Company’s President and CEO, will be presenting at the 2018 BIO Investor Forum at the Westin St. Francis in San Francisco, CA. Details of the presentation are below:
Date: Wednesday, October 17, 2018 Time: 3:45 p.m. PDT Location: Yorkshire Room
About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, clinical-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit www.kedalionthera.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181010005239/en/
CONTACT: Kedalion Therapeutics
Peter Noymer, PhD, +1-650-461-4503
President & CEO
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES OPTICAL PHARMACEUTICAL
SOURCE: Kedalion Therapeutics
Copyright Business Wire 2018.
PUB: 10/10/2018 10:00 AM/DISC: 10/10/2018 10:01 AM